# US 2026/0103456 A1 · Compound, pharmaceutical composition containing same, synthesis method therefor and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0103456 A1
- Document ID: US20260103456A1
- Status: Published application
- Kind: A1
- Application number: 19/116,858
- Filed: 2023-11-21
- Published: 2026-04-16
- Earliest claimed: 2022-11-21
- Assignees: Shenzhen Zhongge Biological Technology Co., Ltd.
- Applicants: Shenzhen Zhongge Biological Technology Co., Ltd.
- Inventors: Bin Cao; Liyu ZHAO; Guosheng DOU; Sizhu LU; Jun YANG; Dewei XIE; Zhaoqiang CHEN; Qihua ZHANG; Shaohui WANG; Bin CHEN; Peiyu ZHANG; Ye TIAN
- Web page: https://patentgrep.com/patent/US20260103456A1

## CPC

- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/4245: Oxadiazoles
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/428: condensed with carbocyclic rings
- A61K 31/433: Thidiazoles
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/497: containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/69: Boron compounds
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 19/00: Drugs for skeletal disorders
- A61P 25/00: Drugs for disorders of the nervous system
- C07B 59/002: {Heterocyclic compounds}
- C07D 271/113: with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/14: containing three or more hetero rings
- C07D 471/08: Bridged systems
- C07D 493/08: Bridged systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07F 5/025: {Boronic and borinic acid compounds}
- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present application provides a compound as shown in formula (0), a pharmaceutical composition containing same, a synthesis method therefore and a use thereof. The compound of the present application can significantly reduce the integrated stress response (ISR) of cells and activate the activity of eIF2B, so that the protein in the cells tends to be synthesized normally, providing more possible drugs for ISR pathway-mediated diseases or condition eIF2B-related diseases, and/or diseases related to regulation of the activity or level of eIF2B activity or level, and regulation of the activity or level of the eIF2 pathway or ISR pathway.

## Claims

### Claim 1

A compound as shown in formula 0, or a stereoisomer thereof, a tautomer thereof, a geometric isomer thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a polymorph thereof, a solvate thereof, a hydrate thereof, an N-oxide thereof, an isotopically labeled compound thereof, a metabolite thereof, an ester thereof, a prodrug thereof or a pharmaceutically acceptable salt thereof:
wherein
ring A is selected from C3-C10 cycloalkylene or 3- to 10-membered heterocycloalkylene, and ring A is not
wherein the * end is connected to L, the end is connected to ring B, and the n3 is any integer from 0-5;
ring B is selected from 5- to 10-membered heteroarylene, and n4 is any integer from 0-4;
ring C is selected from 3- to 10-membered heterocycloalkylene, C3-C10 cycloalkylene, or #B-X21—C3-C12 cycloalkylene-$R1, X21 is —NR3 or —C(O)NR3, #B- represents a connecting bond connected to ring B, and -$R1 represents a connecting bond connected to R1; each R3 is independently H, deuterium, halogen, C1-C6 alkyl or C1-C6 haloalkyl; when ring C is C3-C10 cycloalkylene, ring A is not cyclohexenylene; and when ring A is
the * end is connected to L, the end is connected to ring B, ring C is 3- to 10-membered heterocycloalkylene, and n5 is any integer from 0-5;
ring D is selected from C6-C10 arylene, 5- to 10-membered heteroarylene, C3-C10 cycloalkylene or 3- to 10-membered heterocycloalkylene;
L is #D-L1-L2-L3-$A, 5- to 6-membered heteroaryl or #D-NR14C(O)—C1-C6 alkylene-O-$A, L1 is a bond, —O—, —S— or —NR4—, L2 is a bond, or substituted or unsubstituted C1-C10 alkylene, L3 is —C(X10)NR-$A or —C(X10)-$A, X10 is O or S, R4, R5 and R14 are each independently selected from H, deuterium, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 3- to 10-membered heterocycloalkyl, C6-C10 aryl or 5- to 10-membered heteroaryl; as R4, R5 and R14, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 3- to 10-membered heterocycloalkyl, C6-C10 aryl and 5- to 10-membered heteroaryl may each be independently substituted with 1-6 R11; #D- represents a connecting bond connected to ring D, and -$A represents a connecting bond connected to ring A;
R1, R2, R9a, R9b and R9c are each independently substituent R11;
each R1 is independently selected from deuterium, halogen, cyano, nitro, ═O, —OR6, —SR6, SF5, —NR6R7, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 3- to 10-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, —C(O)R6, —C(O)OR6, —OC(O)OR6, OC(O)R6, —C(O)NR6R7, —C(O)ONR6R7, —NR6C(O)NR7R8, —S(O)1-2R6, —S(O)1-2NR6, NR6S(O)1-2R7, —NR6S(O)1-2NR7R8, —NR6C(O)R7, —P(O)R6R7 or —NR6C(O)OR7, wherein as R9a, R9b, R9c and R11, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 3- to 10-membered heterocycloalkyl, C6-C10 aryl and 5- to 10-membered heteroaryl may each be independently substituted with 1-6 R12;
R6, R7 and R8 are each independently selected from H, deuterium, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 3- to 10-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, —C(O)R20, —C(O)OR20, —C(O)NR20R21, —S(O)1-2R20 and —S(O)1-2NR20, wherein as R6, R7 and R8, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 3- to 10-membered heterocycloalkyl, C6-C10 aryl and 5- to 10-membered heteroaryl may each be independently substituted with 1-6 R13; or
R6 and R7 together with the atom(s) to which they are attached form heterocycloalkyl, and the heterocycloalkyl may be substituted with 1-6 halogen, or substituted with C1-C10 alkyl optionally substituted with 1-6 carbonyl, halogen, hydroxyl or amino; or
R7 and R8 together with the atom(s) to which they are attached form heterocycloalkyl, and the heterocycloalkyl may be substituted with 1-6 halogen, or substituted with C1-C10 alkyl optionally substituted with 1-6 carbonyl, halogen, hydroxyl or amino;
R12 and R13 are each independently H, deuterium, halogen, cyano, nitro, ═O, —OR30, —SR30, —SF5, NR30R31, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 3- to 10-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, —C(O)R30, —C(O)OR30, —OC(O)OR30, OC(O)R30, —C(O)NR30R31, —C(O)ONR30R31, —NR30C(O)NR30R31, —S(O)1-2R30, —S(O)1-2NR30, —NR30S(O)1-2R31, —NR30S(O)1-2NR30R31, —NR30C(O)R31 or —NR30C(O)OR31, wherein as R12 and R13, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 3- to 10-membered heterocycloalkyl, C6-C10 aryl and 5- to 10-membered heteroaryl may each be independently substituted with 1-6 halogen, or substituted with C1-C10 alkyl optionally substituted with 1-6 carbonyl, halogen, hydroxyl or amino;
R20 and R21 are each independently selected from H, deuterium or C1-C10 alkyl optionally substituted with 1-6 halogen, hydroxyl or amino; or
R20 and R21 together with the atom(s) to which they are attached form heterocycloalkyl, and the heterocycloalkyl may be substituted with 1-6 halogen, or substituted with C1-C10 alkyl optionally substituted with 1-6 carbonyl, halogen, hydroxyl or amino;
R30 and R31 are each independently selected from H, deuterium or C1-C10 alkyl optionally substituted with 1-6 halogen, hydroxyl or amino; or
R30 and R31 together with the atom(s) to which they are attached form heterocycloalkyl, and the heterocycloalkyl may be substituted with 1-6 halogen, or substituted with C1-C10 alkyl optionally substituted with 1-6 carbonyl, halogen, hydroxyl or amino;
n1 and n2 are each independently any integer from 0-4.

### Claim 2 (depends on 1)

The compound, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein n4 is 0, 1, 2 or 3; each of the R9b is independently halogen, cyano, nitro, —OH or C1-C3 alkyl; preferably, each of the R9b is independently halogen, —OH, methyl, ethyl or propyl;
preferably, the n4 is 0;
preferably, the ring B is selected from
wherein X7 is O or S, X8, X9 and X10 are each independently CH or N, the * end is connected to ring C, and the end is connected to ring A;
more preferably, at most two of X8, X9 and X10 are N;
further preferably, one of X8, X9 and X10 is N;
preferably, the ring B is selected from any one of the following groups:
further preferably, the ring B is selected from any one of the following groups:
more preferably, the ring B is

### Claim 3 (depends on 1, 2)

The compound, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound has a structure as shown in general formula I
wherein ring A, ring C, ring D, L, R1, R2, R9a, R9c, n1, n2, n2, n3 and n5 are as defined in claim 1 or 2, and X7 is O or S;
preferably, n1 and n2 are each independently an integer from 1-3;
further preferably, n1 is 1, and n2 is an integer from 1-3.

### Claim 4 (depends on 1)

The compound, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein
each of the R9c is independently halogen, cyano, nitro, ═O, —OH, —NR3OR31, C1-C3 alkyl, —C(O)R30 or —C(O)OR30, and R30 and R31 are each independently selected from H, or C1-C3 alkyl optionally substituted with 1-6 halogen, hydroxyl or amino;
preferably, the ring C may be substituted with 1 or 2 R9c, and each of the R9c is independently halogen, cyano, nitro, —OH or C1-C3 alkyl;
further preferably, each of the R9c is independently halogen, —OH, methyl, ethyl or propyl;
more preferably, each of the R9c is independently F or methyl;
preferably, n5 is 0, 1 or 2;
further preferably, n5 is 0 or 1;
preferably, as the ring C, 3- to 10-membered heterocycloalkylene is selected from
wherein X11 and X23 are each N or B, X12 is CH2, NH, O or S, q is an integer from 0-3, and preferably q is 1 or 2; X13 is N or B, and s is an integer from 1-3, preferably s is 1 or 2; X14 is O, S or NH, and t is an integer from 1-3, preferably t is 1 or 2; the * end is connected to ring B, and the end is connected to R1;
further preferably, as the ring C, 3- to 10-membered heterocycloalkylene is selected from
preferably, as the ring C, #B-X21—C3-C12 cycloalkylene-$R1 is
wherein R3 is H, halogen, C1-C3 alkyl or C1-C3 haloalkyl, and p is an integer from 1-3, preferably 1 or 2; the * end is connected to ring B, and the end is connected to R1;
further preferably, as the ring C, #B-X21—C3-C12 cycloalkylene-$R1 is
preferably, the ring C is selected from
the * end is connected to ring B, and the end is connected to R1;
further preferably, the ring C is selected from
more preferably, the ring C is selected from
and q, p, s and t are each independently 1 or 2;
preferably, the
is selected from
the * end is connected to ring B, and the end is connected to R1;
further preferably, the
is selected from
more preferably, the
is selected from

### Claim 5 (depends on 1)

The compound, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein
each of the R1 is independently R11,
each R11 is independently selected from halogen, cyano, nitro, ═O, —OR6, —SR6, —NR6R7, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 3- to 10-membered heterocycloalkyl, —C(O)R6, —C(O)OR6, —OC(O)OR6, —S(O)1-2R6 or —P(O)R6R7, wherein as R11, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl and 3- to 10-membered heterocycloalkyl may each be independently substituted with 1-6 R12;
R6 and R7 are each independently selected from H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl or 3- to 10-membered heterocycloalkyl, wherein as R6 and R7, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl and 3- to 10-membered heterocycloalkyl may each be independently substituted with 1-3 R13;
R12 and R13 are each independently H, halogen, cyano, nitro, ═O, —OR30, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl or 3- to 10-membered heterocycloalkyl, wherein as R12 and R13, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl and 3- to 10-membered heterocycloalkyl may each be independently substituted with 1-3 halogen, or substituted with C1-C3 alkyl optionally substituted with 1-3 carbonyl, halogen, hydroxyl or amino,
each R30 is independently selected from H, or C1-C3 alkyl optionally substituted with 1-6 halogen, hydroxyl or amino;
preferably, the R1 is selected from —OR6, C1-C3 alkyl, halogen, —S(O)2R6 or —P(O)R6R7, wherein as R1, C1-C3 alkyl may be substituted with 1-6 R12, R12 is selected from halogen or —S(O)2R30, and R30 is selected from C1-C3 alkyl, halo C1-C3 alkyl, C3-C6 cycloalkyl or halo C3-C6 cycloalkyl; each R6 is independently selected from C1-C3 alkyl, C2-C4 alkenyl or C3-C6 cycloalkyl, wherein as R6, C1-C3 alkyl, C2-C4 alkenyl or C3-C6 cycloalkyl may each be independently substituted with 1-6 R13, and R13 is halogen; R7 is C1-C3 alkyl;
further preferably, the R1 is selected from —OCH3, —OCF3,
—CF2CF3, —CF3, —OCHF2, —OCF2CF3, —OCF2Cl, —CH2CF3, —F,
—OCF═CF2,
further preferably, the R1 is selected from —OCF3, —CF2CF3, —OCH3, —F,
or —CF3;
further preferably, the R1 is selected from —OCF3 or —OCF2CF3;
more preferably, the R1 is —OCF3;
preferably, n1 is 0 or 1.

### Claim 6 (depends on 1)

The compound, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein
the compound has a structure as shown in general formula II
wherein ring A, ring D, L, R1, R2, R9a, R9c, n1, n2, n3 and n5 are as defined in claim 1;
preferably, the R1 is selected from —OCH3, —OCF3,
—CF2CF3, —CF3, —OCHF2, —OCF2CF3, —OCF2Cl, —CH2CF3, F,
—OCF═CF2,
further preferably, the R1 is selected from —OCH3, —OCF3, —CF2CF3, —F,
or —CF3;
further preferably, the R1 is —OCF3 or —OCF2CF3;
more preferably, the R1 is —OCF3;
preferably, n1 is 1;
preferably, n5 is 0, 1 or 2, and each of the R9c is independently halogen, cyano, nitro, —OH or C1-C3 alkyl;
further preferably, each of the R9c is independently halogen, —OH, methyl, ethyl or propyl;
more preferably, each of the R9c is independently F.

### Claim 7 (depends on 1)

The compound, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein
the compound has a structure as shown in general formula II-1
wherein ring A, ring D, L, R1, R2, R9a, R9c, n1, n2, n3 and n5 are as defined in claim 1;
preferably, n5 is 0 or 1;
preferably, the R9c is selected from halogen, cyano, nitro, —OH or C1-C3 alkyl;
further preferably, the R9c is selected from halogen, methyl or ethyl;
more preferably, the R9c is F;
preferably, the
is selected from
preferably, n1 is 1, the R1 is selected from —OCH3, —OCF3,
—CF2CF3, —CF3, —OCHF2, —OCF2C1, —CH2CF3, —OCF2CF3,
—OCF═CF2,
further preferably, the R1 is selected from —OCH3, —OCF3,
or —OCF2CF3;
further preferably, the R1 is selected from —OCF3 or —OCF2CF3;
more preferably, the R1 is —OCF3.

### Claim 8 (depends on 1)

The compound, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein
n3 is 0, 1 or 2;
preferably, the ring A is selected from C5-C8 cycloalkylene or 5- to 8-membered heterocycloalkylene;
further preferably, the ring A is selected from cyclohexylene or 6-membered heterocycloalkylene;
further preferably, the ring A is selected from cyclohexylene or
the * end is connected to L, and the end is connected to ring B;
preferably, the ring A is selected from
C5-C8 bridged cycloalkylene or 6- to 8-membered bridged heterocycloalkylene, wherein X1 is CH or N, X2, X3, X4, X5 and X6 are each independently CH2, CH, NH, N or O, the * end is connected to L, and the end is connected to ring B;
further preferably, in the
X5 is CH2 or O, and X2, X3, X4 and X6 are each independently CH2 or CH;
further preferably, in the
X2, X3 and X6 are CH2, and X4 is CH;
preferably, as the ring A,
C5-C8 bridged cycloalkylene or 6- to 8-membered bridged heterocycloalkylene may each be independently substituted with 0-4 R9a;
further preferably, the ring A is substituted with 0, 1 or 2 R9a;
more preferably, the ring A is substituted with 0 or 1 R9a;
further preferably, the C5-C8 bridged cycloalkylene is
further preferably, the 6- to 8-membered bridged heterocycloalkylene is
preferably, each of the R9a is independently halogen, cyano, nitro, ═O, —OR6, —SR6, SF5, —NR6R7, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, —C(O)R6, —C(O)OR6, —OC(O)OR6, OC(O)R6, —C(O)NR6R7, —C(O)ONR6R7, —NR6C(O)NR7R8, —S(O)1-2R6, —S(O)1-2NR6, NR6S(O)1-2R7, —NR6S(O)1-2NR7R8, —NR6C(O)R7 or —NR6C(O)OR7, wherein as R9a, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C6-C10 aryl and 5- to 10-membered heteroaryl may each be independently substituted with 1-6 R12;
R6, R7 and R8 are each independently selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, —C(O)R20, —C(O)OR20, —C(O)NR20R21, —S(O)1-2R20 or —S(O)1-2NR20, wherein as R6, R7 and R8, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C6-C10 aryl and 5- to 10-membered heteroaryl may each be independently substituted with 1-4 R13;
R12 and R13 are each independently H, halogen, cyano, nitro, ═O, —OR30, —SR30, SF5, —NR30R31, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, —C(O)R30, —C(O)OR30, —OC(O)OR30, OC(O)R30, —C(O)NR30R31, —C(O)ONR30R31, —NR30C(O)NR30R31, —S(O)1-2R30, —S(O)1-2NR30, NR30S(O)1-2R31, —NR30S(O)1-2NR30R31, —NR30C(O)R31 or —NR30C(O)OR31, wherein as R12 and R13, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C6-C10 aryl and 5- to 10-membered heteroaryl may each be independently substituted with 1-6 halogen, or substituted with C1-C6 alkyl optionally substituted with 1-6 carbonyl, halogen, hydroxyl or amino,
R20 and R21 are each independently selected from H, or C1-C6 alkyl optionally substituted with 1-6 halogen, hydroxyl or amino;
R30 and R31 are each independently selected from H, or C1-C6 alkyl optionally substituted with 1-6 halogen, hydroxyl or amino;
further preferably, each of the R9a is independently halogen, cyano, nitro, ═O, —OH, —NR30R31, C1-C3 alkyl, C1-C3 haloalkyl, —C(O)R30 or —C(O)OR30, and R30 and R31 are each independently selected from H, or C1-C3 alkyl optionally substituted with 1-6 halogen, hydroxyl or amino;
more preferably, each of the R9a is independently halogen, cyano, nitro, ═O, —OH, methyl, ethyl, fluoromethyl or fluoroethyl;
more preferably, each of the R9a is independently —OH or ═O;
more preferably, each of the R9a is independently —OH;
preferably, the
is selected from
the * end is connected to L, and the end is connected to ring B;
further preferably, the
is selected from
further preferably, the
is selected from
more preferably, the
is selected from
more preferably, the
is selected from
more preferably, the
is selected from

### Claim 9 (depends on 1)

The compound, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein
the compound has a structure as shown in general formula III
wherein ring D, L, R1, R2, R9a, R9c, n1, n2, n3 and n5 are as defined in claim 1; X1 and X4 are each independently CH or N, X2, X3, X5 and X6 are each independently CH2, CH, NH, N or C, and v is an integer from 0-2;
preferably, each of the R9a is independently halogen, ═O, —OH or C1-C3 alkyl, more preferably —OH.

### Claim 10 (depends on 1)

The compound, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein
the compound has a structure as shown in any one of general formulas III-1 to III-6
wherein ring D, L, R1, R2, R9a, R9c, n1, n2, n3 and n5 are as defined in claim 1;
preferably, R9a is hydroxyl or halogen;
more preferably, R9a is hydroxyl;
preferably, n3 is an integer from 0-3;
more preferably, n3 is 0, 1 or 2.

### Claim 11 (depends on 1)

The compound, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein
the L is #D-L1-L2-L3-$A,
or #D-NR14C(O)—C1-C6 alkylene-O-$A, L1 is a bond, —O—, —S— or —NR4—, L2 is a bond, or substituted or unsubstituted C1-C3 alkylene, L3 is —C(X10)NR5-$A or —C(X10)-$A, X10 is O or S, R4, R5 and R14 are each independently selected from H, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C6 cycloalkyl or 3- to 6-membered heterocycloalkyl;
as R4, R5 and R14, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C6 cycloalkyl and 3- to 6-membered heterocycloalkyl may each be independently substituted with 1-3 R11; each R11 is independently selected from halogen, cyano, nitro, ═O, —OH, —SH or —NH2, and preferably each R11 is independently selected from halogen, cyano, nitro, —OH, —SH or —NH2; #D- represents a connecting bond connected to ring D, -$A represents a connecting bond connected to ring A, the * end is connected to ring A, and the end is connected to ring D;
preferably, the L is selected from
the * end is connected to ring A, and the end is connected to ring D;
further preferably, the L is selected from
further preferably, the L is selected from
more preferably, the L is selected from

### Claim 12 (depends on 1)

The compound, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein
the compound has a structure as shown in general formula IV-1 or IV-2
wherein ring A, ring C, ring D, R1, R2, R9a, R9c, n1, n2, n3 and n5 are as defined in claim 1, and X7 is O or S;
preferably, the compound has a structure as shown in general formula V-1 or V-2
wherein v is an integer from 0-2, ring D, R1, R2, R9a, R9c, n1, n2, n3 and n5 are as defined in claim 1, X7 is O or S, X1 and X4 are each independently CH or N, and X2, X3, X5 and X6 are each independently CH2, CH, NH, N or C.

### Claim 13 (depends on 1)

The compound, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein
the
is selected from
wherein X14, X15, X16, X17 and X18 are each independently selected from CH or N, with at least one being N, preferably at most three being N, and more preferably at most two being N; X19 and X20 are each independently selected from CH, N, NH, O or S, and are not S or O simultaneously, and m is 1 or 2; X21 and X22 are each independently selected from CH, N, NH, O or S, and are not S or O simultaneously, and m is 1 or 2; u is 1, 2 or 3;
preferably, the
is selected from
further preferably, the
is selected from
further preferably, the
is selected from
further preferably, the
is selected from
more preferably, the
is selected from

### Claim 14 (depends on 1)

The compound, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein
R2 is R11,
each R11 is independently selected from halogen, cyano, nitro, ═O, —OR6, —SR6, —NR6R7, C1-C6 alkyl, C3-C6 cycloalkyl, 3- to 8-membered heterocycloalkyl, —C(O)R6, —C(O)OR6, —OC(O)OR6, OC(O)R6, —C(O)NR6R7 or —C(O)ONR6R7, wherein as R11, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl may each be independently substituted with 1-6 R12;
R6, R7 and R8 are each independently selected from H, C1-C6 alkyl, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, —C(O)R20, —C(O)OR20 or —C(O)NR20R21, wherein as R6, R7 and R8, C1-C6 alkyl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl may each be independently substituted with 1-3 R13;
R12 and R13 are each independently H, halogen, cyano, nitro, ═O, —OR30, NR30R31, C1-C6 alkyl, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, —C(O)R30, —C(O)OR30, —OC(O)OR30 or OC(O)R30, wherein as R12 and R13, C1-C6 alkyl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl may each be independently substituted with 1-3 halogen, or substituted with C1-C3 alkyl optionally substituted with 1-3 carbonyl, halogen, hydroxyl or amino,
R20 and R21 are each independently selected from H, or C1-C3 alkyl optionally substituted with 1-6 halogen, hydroxyl or amino;
R30 and R31 are each independently selected from H, or C1-C3 alkyl optionally substituted with 1-6 halogen, hydroxyl or amino;
n2 is 1, 2 or 3;
preferably, each R2 is independently selected from halogen, cyano, C1-C3 haloalkyl, C1-C3 alkyl, —OC1-C3 alkyl, —O C1-C3 haloalkyl, —NR6R7, C3-C6 cycloalkyl or 3- to 6-membered heterocycloalkyl, R6 and R7 are each independently selected from H, C1-C3 alkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl or C3-C6 halocycloalkyl, preferably, when the R2 is C3-C6 cycloalkyl or 3- to 6-membered heterocycloalkyl, n is 1, and the R2 and the ring D share two carbon atoms to form a fused ring;
further preferably, each R2 is independently selected from halogen, C1-C3 haloalkyl, C1-C3 alkyl, —O—C1-C3 alkyl, —O—C1-C3 haloalkyl, —NH2 or
wherein when R2 is
and the ring D share two carbon atoms to form a fused ring;
further preferably, each R2 is independently selected from F, Cl, Br, —CF3, —CH3, —CF2H, —OCF3 or —NH2, and n2 is 1, 2 or 3;
preferably, the
is selected from
further preferably, the
is selected from
further preferably, the
is selected from
further preferably, the
is selected from
more preferably, the
is selected from

### Claim 15 (depends on 1)

The compound, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein
the compound has a structure as shown in general formula VI
wherein the ring A is selected from cyclohexylene or 6-membered heterocycloalkylene; the L, R1, R2, R9a, R9c, n1, n2, n3 and n5 are as defined in claim 1;
preferably, each of the R2 is independently selected from F, Cl or Br;
preferably, the n2 is 1 or 2;
preferably, the R2 is in a para-position relationship and/or a meta-position relationship with L;
preferably, the L is selected from
the * end is connected to ring A, and the end is connected to ring D;
further preferably, the L is selected from
further preferably, the L is selected from
more preferably, the L is selected from
preferably, the n1 and n5 are not 0 simultaneously;
preferably, the R1 is in a para-position relationship with the N on the C ring where the R1 is located;
preferably, the R1 is selected from —OR6, C1-C3 alkyl, halogen, —S(O)2R6 or —P(O)R6R7, wherein as R1, C1-C3 alkyl may be substituted with 1-6 R12, R12 is selected from halogen or —S(O)2R30, and R30 is selected from C1-C3 alkyl, halo C1-C3 alkyl, C3-C6 cycloalkyl or halo C3-C6 cycloalkyl; each R6 is independently selected from C1-C3 alkyl, C2-C4 alkenyl or C3-C6 cycloalkyl, wherein as R6, C1-C3 alkyl, C2-C4 alkenyl or C3-C6 cycloalkyl may each be independently substituted with 1-6 R13, and R13 is halogen; R7 is C1-C3 alkyl;
further preferably, the R1 is —OCH3, —OCF3,
—CF2CF3, —CF3, —OCHF2, —OCF2CF3, —OCF2Cl, —CH2CF3, —F,
—OCF═CF2,
further preferably, the R1 is —OCF3, —CF2CF3, —OCH3, —F,
or —CF3;
further preferably, the R1 is —OCF3 or —OCF2CF3;
more preferably, the R1 is —OCF3.

### Claim 16 (depends on 1)

The compound, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound has a structure as shown in general formula VII
wherein R9a and X10 are as defined in claim 1, R21 is halogen, R22 is selected from H or halogen, and t is selected from an integer from 0-2;
preferably, R21 is C1;
preferably, R22 is selected from H, F, Cl or Br;
preferably, R9a is selected from H or hydroxyl;
preferably, t is 0 or 2.

### Claim 17 (depends on 1)

The compound, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is selected from:
preferably, the compound is selected from:

### Claim 18 (depends on 12)

A method for synthesizing the compound having a structure as shown in general formula IV-1 or IV-2, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 12, wherein the synthesis method is selected from any one of synthesis routes 1 to 6;
wherein compound 1-1 is subjected to an amide condensation reaction with compound 1-2 to obtain compound 1-3; the compound 1-3 is reacted with hydrazine hydrate and subjected to a functional group conversion to obtain compound 1-4; the compound 1-4 is subjected to a cyclization with N,N′-carbonyldiimidazole to obtain compound 1-5; the compound 1-5 is subjected to a condensation reaction with compound 1-6 to obtain compound IV-1-1; and R1, R2, R9a, R9c, n1 and n2 are as defined in claim 12;
wherein compound 2-1 is subjected to an amide condensation reaction with compound 2-2 to obtain compound 2-3; the compound 2-3 is reacted with hydrazine hydrate and subjected to a functional group conversion to obtain compound 2-4; the compound 2-4 is subjected to a cyclization with N,N′-carbonyldiimidazole to obtain compound 2-5; the compound 2-5 is subjected to a condensation reaction with compound 2-6 to obtain compound IV-2-1; and R1, R2, R9a, R9c, n1 and n2 are as defined in claim 12;
wherein compound 3-1 is reacted with hydrazine hydrate and subjected to a functional group conversion to obtain compound 3-2; the compound 3-2 is subjected to a cyclization with N,N′-carbonyldiimidazole to obtain compound 3-3; the compound 3-3 is subjected to a condensation reaction with compound 3-4 to obtain compound 3-5; the compound 3-5 is subjected to protecting group removal under an acidic condition to obtain compound 3-6; the compound 3-6 is subjected to an amide condensation reaction with compound 3-7 to obtain compound IV-1-1; and R1, R2, R9a, R9c, n1 and n2 are as defined in claim 12;
wherein compound 4-1 is reacted with hydrazine hydrate and subjected to a functional group conversion to obtain compound 4-2; the compound 4-2 is subjected to a cyclization with N,N′-carbonyldiimidazole to obtain compound 4-3; the compound 4-3 is subjected to a condensation reaction with compound 4-4 to obtain compound 4-5; the compound 4-5 is subjected to protecting group removal under an acidic condition to obtain compound 4-6; the compound 4-6 is subjected to an amide condensation reaction with compound 4-7 to obtain compound IV-2-1; and R1, R2, R9a, R9c, n1 and n2 are as defined in claim 12;
wherein compound 5-1 is subjected to an amide condensation reaction with compound 5-2 to obtain compound 5-3; the compound 5-3 is reacted with hydrazine hydrate and subjected to a functional group conversion to obtain compound 5-4; the compound 5-4 is subjected to a condensation reaction with compound 5-5 to obtain compound 5-6; the compound 5-6 is subjected to a ring-closing reaction to obtain compound IV-1-1; and R1, R2, R9a, R9c, n1 and n2 are as defined in claim 12;
wherein compound 6-1 is reacted with hydrazine hydrate and subjected to a functional group conversion to obtain compound 6-2; the compound 6-2 is subjected to a ring-closing reaction to obtain compound 6-3; the compound 6-3 is subjected to an oxidation reaction to obtain compound 6-4; the compound 6-4 is reacted with compound 6-5 to obtain compound 6-6; the compound 6-6 is subjected to protecting group removal under an acidic condition to obtain compound 6-7; the compound 6-7 is subjected to a condensation with compound 6-8 to obtain compound IV-1-1; and R1, R2, R9a, R9c, n1 and n2 are as defined in claim 12.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising a preparation prepared from the compound, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 1.

### Claim 20 (depends on 19)

The pharmaceutical composition according to claim 19, further comprising a pharmaceutically acceptable carrier, excipient and vehicle.

### Claim 21 (depends on 1)

A method for preventing and/or treating neurodegenerative diseases, cancer, inflammatory diseases, autoimmune diseases, viral infections, skin diseases, fibrotic diseases, hemoglobin diseases, kidney diseases, hearing loss diseases, eye diseases, diseases with mutations causing the induction of unfolded protein response (UPR), malaria infections, musculoskeletal diseases, metabolic diseases or mitochondrial diseases, wherein the method comprises administering an effective amount of the compound, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 1 to a subject in need thereof.

### Claim 22 (depends on 1)

A method for preventing and/or treating a disease or condition mediated by an integrated stress response (ISR) pathway, wherein the method comprises administering an effective amount of the compound, or the stereoisomer thereof, the tautomer thereof, the geometric isomer thereof, the enantiomer thereof, the diastereomer thereof, the racemate thereof, the polymorph thereof, the solvate thereof, the hydrate thereof, the N-oxide thereof, the isotopically labeled compound thereof, the metabolite thereof, the ester thereof, the prodrug thereof or the pharmaceutically acceptable salt thereof according to claim 1 to a subject in need thereof.
